{"nctId":"NCT05161806","briefTitle":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe","startDateStruct":{"date":"2022-03-11","type":"ACTUAL"},"conditions":["Neovascular Age-related Macular Degeneration (nAMD)"],"count":30,"armGroups":[{"label":"SOK583A1 (40 mg/mL)","type":"EXPERIMENTAL","interventionNames":["Drug: SOK583A1 (40 mg/mL)","Device: Prefilled Syringe (PFS)"]}],"interventions":[{"name":"SOK583A1 (40 mg/mL)","otherNames":["aflibercept"]},{"name":"Prefilled Syringe (PFS)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects ≥ 50 years of age at baseline\n* Subjects diagnosed with nAMD (uni- or bilateral)\n* Subjects already under IVT Eylea treatment (last injection of the induction period or maintenance phase)\n\nExclusion Criteria:\n\n* Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or autoimmune associated uveitis or endophthalmitis\n* Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 26 mmHg, despite treatment with anti-glaucomatous medication)\n* History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of investigational product\n* Visual Acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness\n* Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment\n* Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening)\n* Subjects who do not comply with the local COVID-19 regulations of the study site","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Ocular Treatment Emergent Adverse Events","description":"Number of participants with ocular treatment emergent adverse events were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Non-ocular Treatment Emergent Adverse Events","description":"Number of participants with non ocular Treatment emergent adverse events were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Foreign body sensation in eyes","Intraocular pressure increased","Hypertension","Ocular discomfort"]}}}